We are making drugs safer through the analysis of data. Everyday millions of us or our loved ones take medications to manage our health. We trust in these prescriptions to improve our lives and give us hope for a healthier future. Often, however, these drugs have harmful side effects or dangerous interactions. Adverse drug reactions are experienced by millions of patients each year and cost the healthcare industry billions of dollars. In the Tatonetti Lab we use advanced data science methods, including artificial intelligence and machine learning, to investigate these medicines. Using emerging resources, such as electronic health records (EHR) and genomics databases, we are working to identify for whom these drugs will be safe and effective and for whom they will not. Browse our databases, contribute to our projects, and join us on this journey to make precision pharmacology a realty.
Phyllis presents and takes top poster prize at MD-PhD Symposium
Phyllis Thangaraj, MD/PhD Candidate in the lab, presents her work on developing automated stroke phenotyping algorithms for the electronic health records at Columbia’s 14th Annual MD-PhD Student Research Symposium on April 25th, 2019. In addition, she was one of five poster competition winners!
Nick speaks at the GM XII about scientific discovery using the EHR
The 12th meeting on Genome Medicine hosted by the National Human Genome Research Institute focused on Genomics and Risk Prediction in Silver Spring, MD. Dr. Tatonetti speaks to the group about how to use commonly collected hospital data to infer millions of familial relationships between patients and use this novel resource to study disease heritability, stroke phenotyping, and risk stratification. Watch the whole video here. Nick starts at 22:22.
Calculated Risk by Shraddha Chakradhar in Nature Medicine
The Tatonetti Lab’s work is featured in the latest issue of Nature Medicine in “Calculated Risk” by Nature staff writer, Shraddha Chakradhar. Read about the moment of discovery that propelled the lab into the field of drug safety, pharmacovigilance, and drug-drug interactions here.